The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax

20242 citationsJournal Articlegold Open Access

Authors

Our results substantiate the development of SpiD3 as a novel therapeutic agent for relapsed/refractory CLL disease.

Good health and well-being

Published in: Hemato

Volume 5, Issue 3, pp. 321-340

Field-Weighted Citation Impact: 0.88